country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P991455

Copy Link Print Information

Biologically Validated

PTX-35

Avis client

Based on 1 Customer Validation

PTX-35 is a costimulatory agonist antibody targeting TNFRSF25 as well as an immune activator that selectively regulates activated CD8⁺ T cells. PTX-35 enhances the expansion, survival and effector functions of T cells, while reducing the inhibitory activity of regulatory T cells and impairing their stability. PTX-35 exhibits anti-tumor activity, effectively delaying tumor progression and prolonging survival. PTX-35 has a synergistic effect with anti-OX40 agonist antibodies. PTX-35 can be widely used in research on related diseases such as colon cancer and melanoma.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 98.95%
Masse moléculaire:145.58 kDa

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

PTX-35 Chemical Structure

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vivo
- Essai clinique
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Application
- Verified Bioactivity
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Isotype

Human IgG1 lambda2

Recommend Isotype Controls

Human IgG1 lambda2, Isotype Control

Species Reactivity

Human

IC₅₀ & Target

TNFRSF25

Voir tous les produits spécifiques à Isoform TNF Receptor :

In Vivo

Mouse PTX-35 (mPTX-35) , in the presence of tumor antigens, reprograms the Treg cell phenotype by reducing Treg suppressive activity and increasing Treg plasticity toward inflammatory Th1 and Th17 cells, which is associated with delayed tumor progression in a murine melanoma model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Gene ID

8718 [NCBI]

Accession

Q93038

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Application

ELISA, FACS, Functional assay

Verified Bioactivity

Immobilized Human-DR3-his can bind PTX-35. The EC₅₀ for this effect is 69.63 ng/mL.

Chemical Information

Appearance Liquid
Masse moléculaire 145.58 kDa
Color Colorless to light yellow
SMILES

[3H][P][F,Cl,Br,I]
Livraison

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (258 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

Références

[1]. Tahiliani V, et al. Abstract 2224A: A novel TNFRSF25 agonist, PTX35, synergizes with Gp96-Ig/OX40L-Ig to enhance effector and memory anti-tumor CD8+ T cell responses and delay tumor growth[J]. Cancer Research, 2020, 80(16_Supplement): 2224A-2224A.

[2]. Kalim K W, et al. PTX-35, a potential first-in-class TNFRSF25 agonist, reduced the suppressive activity of regulatory T cells and enhanced CD4+ T cell effector responses, in the presence of tumor antigens, in a murine melanoma model[J]. Cancer Research, 2021, 81(13_Supplement): 604-604.

[3]. Simons F E R. Advances in H1-antihistamines[J]. New England Journal of Medicine, 2004, 351(21): 2203-2217.

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Obtenir un devis En stock

Amount: USD 0.00

Activité biologique
- Description
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vivo
- Essai clinique
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Application
- Biological Activity
Chemical Information
Pureté et documentation
Références

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

PTX-35

Cytotoxicity LDH Assay Kit

PBS Buffer (1×)

DPBS Buffer (1×)

Antibody Inhibitor Library

Voir tous les produits spécifiques à Isoform TNF Receptor

Activité biologique

Chemical Information

Pureté et documentation

Références

Calculators

Help & FAQs

PTX-35 Related Classifications

HY-P991455 Related Classifications